1-9 of 9
Jens Wuerthner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Qpctl Inhibition, By Targeting the Inflammatory Tumor Microenvironment, Constitutes a Novel Therapeutic Approach for Diffuse Large B-Cell Lymphoma

Nicolas Di Siervi, Jasper Mullender, María Victoria Revuelta, Nahuel Zamponi, Eloisi Caldas-Lopes, Yusuke Isshiki, Wendy Béguelin, Marcel Scheepstra, Bastiaan Evers, Jens Wuerthner, Leandro Cerchietti
Journal: Blood
Blood (2023) 142 (Supplement 1): 49.
https://doi.org/10.1182/blood-2023-181264
Published: 2023
Journal Articles

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Alex F. Herrera, Stephen M. Ansell, Pier Luigi Zinzani, John Radford, Kami J. Maddocks, Antonio Pinto, Graham P. Collins, Veronika Bachanova, Nancy L. Bartlett, Isabelle Bence-Bruckler, Mehdi Hamadani, Justin Kline, Jiri Mayer, Kerry J. Savage, Ranjana H. Advani, Paolo F. Caimi, René-Olivier Casasnovas, Tatyana A. Feldman, Brian T. Hess, Mariana Bastos-Oreiro, Sunil Iyengar, Árpád Szomor, William Townsend, Marc Andre, Jerzy Dyczkowski, Sandy Eisen, Andrzej Urban, Serafino Pantano, Hans G. Cruz, Luqiang Wang, Yanina Negievich, Jens Wuerthner, Carmelo Carlo-Stella
Journal: Blood
Blood (2022) 140 (Supplement 1): 3673–3677.
https://doi.org/10.1182/blood-2022-157583
Published: 2022
Journal Articles

CD25, Soluble CD25, and CCL17 As Potential Predictors of Clinical Response to Camidanlumab Tesirine in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Jerzy Dyczkowski, Alex F. Herrera, Carmelo Carlo-Stella, Pier Luigi Zinzani, Marie Toukam, Hans G. Cruz, Karin Havenith, Joseph Boni, Jens Wuerthner, Serafino Pantano
Journal: Blood
Blood (2022) 140 (Supplement 1): 9306–9308.
https://doi.org/10.1182/blood-2022-157748
Published: 2022
Journal Articles

Identification of Predictive Biomarkers for Response of R/R DLBCL Patients Treated with Loncastuximab Tesirine Using Low Pass Whole-Genome Sequencing (WGS)

Francesco Vallania, Victoria Cheung, Michael D. Zamba, Joyce Liu, Amit Pasupathy, Hayley Donnella, Mitch Bailey, Maggie Louie, Jimmy Lin, Karin Havenith, Yajuan Qin, Serafino Pantano, Jens Wuerthner, Patrick H van Berkel
Journal: Blood
Blood (2022) 140 (Supplement 1): 3551–3552.
https://doi.org/10.1182/blood-2022-168993
Published: 2022
Journal Articles

Pharmacokinetic and Pharmacodynamic Correlates from the Phase 1 Study of Camidanlumab Tesirine (Cami) in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Joseph Boni, Karin Havenith, Mehdi Hamadani, MD, Paolo F Caimi, MD, Katie Anderson, Tim Kopotsha, Hans G Cruz, Jens Wuerthner
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–36.
https://doi.org/10.1182/blood-2020-137011
Published: 2020
Journal Articles

Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma

Alex F. Herrera, MD, Carmelo Carlo-Stella, MD, Graham P. Collins, MD DPhil, Kami J. Maddocks, MD, Nancy L. Bartlett, MD, Kerry J. Savage, MDMSc, Paolo F Caimi, Brian T. Hess, MD, Pier Luigi Zinzani, MD, Hans G Cruz, Luqiang Wang, Jay Feingold, Jens Wuerthner, Stephen M. Ansell, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–23.
https://doi.org/10.1182/blood-2020-137451
Published: 2020
Journal Articles

Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

Mehdi Hamadani, MD, Graham P. Collins, MB BS DPhil, Felipe Samaniego, MD, Alexander I Spira, MD, Andrew Davies, John Radford, MD FRCP, Paolo Caimi, MD, Tobias Menne, MD PhD, Joseph Boni, PhD, Hans Cruz, Jay Feingold, MD PhD, Shui He, PhD, Jens Wuerthner, Steven M. Horwitz, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 928.
https://doi.org/10.1182/blood-2018-99-118198
Published: 2018
Journal Articles

Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma

Graham P. Collins, MB BS DPhil, Steven M. Horwitz, MD, Andrew Davies, Anand Karnad, MD, Felipe Samaniego, MD, Alexander I Spira, MD, Paul A Fields, MD PhD, Tobias Menne, MD PhD, Joseph Boni, PhD, Hans Cruz, Jay Feingold, MD PhD, Shui He, PhD, Jens Wuerthner, Mehdi Hamadani, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1658.
https://doi.org/10.1182/blood-2018-99-115986
Published: 2018
Journal Articles

The MDM2 Inhibitor NVP-CGM097 Is Highly Active in a Randomized Preclinical Trial of B-Cell Acute Lymphoblastic Leukemia Patient Derived Xenografts

Elizabeth C Townsend, PhD, Tiffany DeSouza, B.S., Mark A. Murakami, MD MA, Joan Montero, PhD, Kristen Stevenson, MS, Amanda L Christie, B.S., Alexandra N Christodolou, M.Sc., Una Vojinovic, B.S., Nadja Kopp, M.S., Patrizia Barzaghi-Rinaudo, Masato Murakami, MD, PhD, Anthony Letai, MD PhD, Sebastien Jeay, Jens Wuerthner, Ensar Halilovic, David M. Weinstock
Journal: Blood
Blood (2015) 126 (23): 797.
https://doi.org/10.1182/blood.V126.23.797.797
Published: 2015